|
Market Closed -
London S.E.
16:35:27 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 194.00 GBX | -0.51% |
|
-4.90% | +51.56% |
| 11-13 | RBC Capital Markets Boosts Diaceutics PT, Keeps at Outperform | MT |
| 11-13 | Peel Hunt raises Asos and cuts Dr Martens | AN |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 85.75 | 63.68 | 73.32 | 106.1 | 108.7 | 164.7 | - | - |
| Change | - | -25.74% | 15.14% | 44.67% | 2.47% | 51.52% | - | - |
| Enterprise Value (EV) 1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 156.9 | 154.2 | 149.2 |
| Change | - | -33.66% | 29.24% | 64.73% | 8.6% | 54.79% | -1.68% | -3.26% |
| P/E | - | 89.9x | -42x | -62.1x | - | - | - | - |
| PBR | - | 1.53x | 1.8x | 2.66x | 2.67x | 3.91x | 3.47x | 2.99x |
| PEG | - | - | 0x | 25.71x | - | - | - | - |
| Capitalization / Revenue | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 3.53x | 2.91x | 2.42x |
| EV / Revenue | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 3.36x | 2.72x | 2.19x |
| EV / EBITDA | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 15.3x | 11.1x | 8.1x |
| EV / EBIT | 120x | 76.4x | -18.8x | -38x | 57.5x | 49x | 28.6x | 17.2x |
| EV / FCF | -13.1x | 194x | -16x | -23.4x | -19.2x | 223x | 55.1x | 32.1x |
| FCF Yield | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.45% | 1.82% | 3.12% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1 |
| Rate of return | - | - | - | - | - | - | - | 51.5% |
| EPS 2 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 46.69 | 56.66 | 68.12 |
| EBITDA 1 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.23 | 13.92 | 18.43 |
| EBIT 1 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 5.391 | 8.68 |
| Net income 1 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 2.85 | 6.05 |
| Net Debt 1 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.809 | -10.45 | -15.47 |
| Reference price 2 | 1.020 | 0.755 | 0.870 | 1.255 | 1.280 | 1.940 | 1.940 | 1.940 |
| Nbr of stocks (in thousands) | 84,069 | 84,339 | 84,274 | 84,515 | 84,912 | 84,886 | - | - |
| Announcement Date | 22/03/22 | 17/04/23 | 21/05/24 | 13/05/25 | 26/05/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 3.38x | 15.46x | -.--% | 219M | |
| 28.23x | 15.66x | 22.2x | 0.74% | 793B | |
| 41.28x | 7.5x | 26.62x | 0.87% | 90.34B | |
| 23.46x | 4.71x | 10.27x | 0.69% | 70.53B | |
| 50.89x | 1.81x | 10.05x | -.--% | 49.73B | |
| 11.49x | 1.49x | 7.37x | 0.97% | 48.43B | |
| -59.91x | 15.63x | 36.3x | -.--% | 35.26B | |
| 21.18x | 3.53x | 8.36x | 1.52% | 33.41B | |
| -14.74x | 2.97x | 7.08x | -.--% | 32.72B | |
| 22.37x | 6.5x | 12.37x | -.--% | 29.17B | |
| Average | 13.80x | 6.32x | 15.61x | 0.48% | 118B | |
| Weighted average by Cap. | 25.05x | 12.30x | 20.08x | 0.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
